The phase 1 POD1UM-101 trial, presented at the 2023 ESMO Congress, showed that retifanlimab-dlwr is effective and well-tolerated in treating recurrent microsatellite instability–high or mismatch repair–deficient endometrial cancer. With a 26-month follow-up, retifanlimab-dlwr achieved a 51.3% objective response rate in 76 patients. The study, noting a median overall survival of 30.2 months and common side effects like fatigue and diarrhea, highlights the potential of retifanlimab for advanced or metastatic endometrial cancer treatment.
Reference: Rosa K. Retifanlimab Continues to Elicit Responses in Recurrent MSI-H or dMMR Endometrial Cancer. OncLive. Published November 28, 2023. Accessed December 20, 2023. https://www.onclive.com/view/retifanlimab-continues-to-show-activity-in-recurrent-msi-h-or-dmmr-endometrial-cancer
